Fc-Elabela mitigates heart failure without liver and renal toxicity in mice.

ABSTRACT:

Aims

Elabela (ELA) is a ligand of the APJ receptor and exhibits anti-heart failure activities. However, the short half-life of the ELA limits its clinical applications. Our previous study recombined the short peptide ELA-21 and the Fc fragment of human IgG into a long-acting Fc-ELA-21 fusion protein and has shown that Fc-ELA-21'half-life in mice is 44 h and retained activation of the APJ receptor to exert anti-heart failure activity However, the anti-heart failure mechanisms of Fc-ELA-21 are still unclear, and its optimal dose range and long-term in vivo safety profile remain undefinedThis study aimed to investigate the anti-heart failure mechanisms of Fc-ELA-21, dose range, and in vivo safety.

Methods and results

We investigated the effects of different doses of Fc-E

SUBMITTER: Zhou H 

PROVIDER: S-EPMC12301219 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature